AAVXF:OTCMKTS
Abivax SA
US$139,00
0,00%
(0,00) 1 HR
9 Jul, 09.30.01 GMT-4 · USD
search
Semua simbol
| Simbol | Harga | Perubahan | Persentase Perubahan |
|---|
insights_autoMembuat insight teratas untuk AAVXF...
Kapitalisasi pasar
6,71 M
Volume rata-rata
0,00
Volume
0,00
Harga tinggi dalam 52 minggu terakhir
US$139,00
Harga rendah dalam 52 minggu terakhir
US$71,26
Beta
3,09
Saham beredar
87,53 jt
Jumlah karyawan
98
Kapitalisasi pasar
6,71 M
Volume rata-rata
0,00
Volume
0,00
Harga tinggi dalam 52 minggu terakhir
US$139,00
Harga rendah dalam 52 minggu terakhir
US$71,26
Beta
3,09
Saham beredar
87,53 jt
Jumlah karyawan
98
Artikel berita
Dari sumber web dan partner berita
www.dars.gov.et
·
3 hari yang lalu
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline - Profit Announcement
Profil
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Tentang Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Karyawan98
Didirikan4 Des 2013
Kantor Pusat-
Sektor-
Situsabivax.com